London – February 16, 2023 – Bavarian Nordic, a vaccine company, has entered into a definitive agreement to acquire Emergent BioSolutions’ travel vaccines portfolio for up to $380 million, including an upfront payment of $270 million. Partners Michal Berkner and John Wilkinson led the Cooley team.
The deal will add two marketed travel vaccines, a late-stage vaccine candidate, and research, development, manufacturing and commercial capabilities to Bavarian Nordic’s portfolio. The vaccines included in the deal are Vivotif for the prevention of typhoid fever, Vaxchora against cholera and a phase 3 vaccine candidate for the prevention of chikungunya virus.
Bavarian Nordic is a fully integrated vaccines company focused on the research and development, manufacturing and commercialization of lifesaving vaccines. The company is a global leader in smallpox and mpox vaccines, which have been developed through a long-standing partnership with the US government to enhance public health preparedness. Bavarian Nordic’s commercial product portfolio also contains market-leading vaccines against rabies and tick-borne encephalitis. Using its live virus vaccine platform technology (MVA-BN) and in-licensed technologies, Bavarian Nordic has created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including phase 3 development programs for a respiratory syncytial virus (RSV) vaccine for older adults and a next-generation COVID-19 vaccine.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.